Who are Ellence's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Chromic Chloride In Plastic Container, Inbrija, Aurolate, ACETIC ACID, Idamycin Pfs, Idamycin Pfs.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/epirubicin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Ellence — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ellence (EPIRUBICIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anthracycline Topoisomerase Inhibitor. Area: Oncology.

marketed Anthracycline Topoisomerase Inhibitor Tyrosine-protein kinase Fyn Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Ellence (EPIRUBICIN) — Pfizer. Ellence works by intercalating DNA and inhibiting topoisomerase II, disrupting cancer cell growth.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ellence TARGET	EPIRUBICIN	Pfizer	marketed	Anthracycline Topoisomerase Inhibitor	Tyrosine-protein kinase Fyn	1999-01-01
Chromic Chloride In Plastic Container	CHROMIC CHLORIDE	Pfizer	marketed		Epidermal growth factor receptor, Tyrosine-protein kinase Fyn	1986-01-01
Inbrija	LEVODOPA	Merz	marketed	Aromatic Amino Acid [EPC]	Tyrosine-protein kinase Fyn	1970-01-01
Aurolate	sodium aurothiomalate		marketed	sodium aurothiomalate	Tyrosine-protein kinase Fyn
ACETIC ACID	ACETIC ACID, GLACIAL	CHARTWELL RX	marketed		Free fatty acid receptor 3, Tyrosine-protein kinase Fyn, Tyrosine-protein kinase Lck
Idamycin Pfs	IDARUBICIN HYDROCHLORIDE		marketed	Anthracycline Topoisomerase Inhibitor	DNA, topoisomerase II	1990-01-01
Idamycin Pfs	Idarubicin Hydrochloride	Pfizer Inc.	marketed	Anthracycline topoisomerase inhibitor	DNA, Topoisomerase II	1990-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-02-03 — Inbrija · RE43711 · Method of Use · US
2032-11-16 — Inbrija · 8685442 · Formulation · US
2032-11-16 — Inbrija · 8945612 · Formulation · US
2032-11-16 — Inbrija · 8545878 · Formulation · US
2032-11-16 — Inbrija · 9393210 · Formulation · US
2033-10-21 — Inbrija · 12458615 · Method of Use · US

Sponsor landscape (Anthracycline Topoisomerase Inhibitor class)

· 2 drugs in this class
Pfizer · 2 drugs in this class
Meiji Seika Pharma Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ellence — Competitive Intelligence Brief. https://druglandscape.com/ci/epirubicin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing